Table 1_Continuing immune checkpoint inhibitors beyond progression versus switching to non

A retrospective study of 169 patients with advanced gastric or gastroesophageal junction cancer who progressed after first-line immuno-chemotherapy. It compares survival outcomes between continuing immune checkpoint inhibitors beyond progression (n=120) versus switching to non-ICI therapy (n=49). The dataset was authored by Guangxi Wang and last updated on 2026-06-03.

Use Cases

• Compare progression-free survival (PFS) and overall survival (OS) between two second-line treatment strategies based on real-world data.
• Identify patient subgroups (e.g., PD-L1 expression ≥1%) that benefit most from continuing immunotherapy based on subgroup analyses mentioned.
• Analyze the safety profile of continuing immunotherapy beyond progression versus switching to alternative regimens.
• Validate clinical trial findings on immunotherapy efficacy using real-world observational data.

Strengths

• Includes data from 169 patients, providing a substantive real-world cohort for analysis.
• Reports specific median survival outcomes: PFS of 4.4 vs. 3.0 months and OS of 9.5 vs. 6.4 months.
• Analyses were adjusted using multivariable methods and propensity score matching, suggesting methodological rigor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center, retrospective study, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Single-center, retrospective study.

Freshness

Last updated 2026-06-03 04:47:38; freshness should be verified.